The study involves testing epcoritamab, administered subcutaneously, in combination with oral and intravenous anti-neoplastic agents. These include drugs like lenalidomide, ibrutinib, and polatuzumab ...

FDA approval of blockbuster AbbVie drug Rinvoq makes it the first oral therapy for moderately to severely active Crohn's disease. The regulatory nod is the seventh for the drug, which belongs to a ...

The study tests the combination of two drugs: Venetoclax, an oral tablet, and Azacitidine, which can be administered as an oral tablet or via subcutaneous or intravenous injection.

June 3 (Reuters) - Johnson & Johnson JNJ.N and AbbVie's ABBV.N big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more ...

Positive preclinical data for AbbVie's new oral cancer medication, ABBV-CLS-484, shows it 'enhances anti-tumor immunity.' AbbVie's oral cancer drug trial shows it may provide 'anti-tumor immunity' ...

AbbVie Inc's all-oral hepatitis C therapy cured 96 percent of difficult-to-treat patients in a late-stage clinical trial after 12 weeks, keeping the company well placed in a highly competitive ...

NORTH CHICAGO, Ill., Dec. 16, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted a supplemental New Drug Application (sNDA) for linaclotide (LINZESS®) to the U.S. Food ...

Study results show 51% of patients treated with the AbbVie drug developed peripheral neuropathy; 11% of those cases were classified as Grade 3. This complication led 13% of trial participants to ...

AbbVie ABBV announced that a phase III study evaluating its oral JAK inhibitor, Rinvoq (upadacitinib) in patients with moderate-to-severe atopic dermatitis (“AD”) met both primary endpoints ...

Positive preclinical data for AbbVie's new oral cancer medication, ABBV-CLS-484, shows it 'enhances anti-tumor immunity.' ...

AbbVie Inc's all-oral hepatitis C therapy cured 96 percent of difficult-to-treat patients in a late-stage clinical trial after 12 weeks, keeping the company well placed in a highly competitive ...